| 词条 | Vandortuzumab vedotin |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = zu/o | target = STEAP1 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1471985-92-8 | ATC_prefix = none | ATC_suffix = | PubChem = | ChemSpiderID = none | DrugBank = | C = 6608 | H = 10168 | N = 1756 | O = 2076 | S = 44 | molecular_weight = 156-160 kDa | UNII = 44OUQ00D1U | KEGG = D11002 | synonyms = RG7450 }}Vandortuzumab vedotin (RG7450) (INN) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2] This drug was developed by Genentech/Roche. Development was discontinued in 2017.[3] References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin, American Medical Association. {{monoclonals for tumors}}{{monoclonal-antibody-stub}}2. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112 | journal = WHO Drug Information | volume = 28 | issue = 4 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}} 3. ^{{cite web |title=Vandortuzumab vedotin - AdisInsight |url=https://adisinsight.springer.com/drugs/800033873 |website=adisinsight.springer.com}} 2 : Monoclonal antibodies|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。